MyoKardia is a technology company.
MyoKardia has raised $10.0M across 1 funding round.
Key people at MyoKardia.
MyoKardia has raised $10.0M in total across 1 funding round.
MyoKardia has raised $10.0M in total across 1 funding round.
MyoKardia's investors include Third Rock Ventures.
Key people at MyoKardia.
MyoKardia is a biopharmaceutical company, not a technology company in the software or hardware sense, focused on developing precision medicines for cardiovascular diseases (CVDs), particularly hypertrophic cardiomyopathy (HCM).[1][3][5] It builds targeted therapies like the small molecule mavacamten, which addresses the underlying cause of HCM by inhibiting cardiac myosin to reduce excessive heart muscle contraction.[1][6] Serving patients with serious heart conditions such as HCM and dilated cardiomyopathy, MyoKardia solves the problem of heterogeneous CVDs by subtyping patient populations for more effective, transformative treatments rather than symptomatic relief.[1][3][6] The company achieved significant growth momentum, completing Phase III trials in eight years from founding, submitting its first drug (mavacamten) to the FDA, and culminating in a $13.1 billion acquisition by Bristol Myers Squibb.[1][4]
Founded in 2012 in California, MyoKardia emerged amid rising momentum in precision medicine, inspired by successes like Vertex's ivacaftor for cystic fibrosis and companies such as Foundation Medicine, Agios, and bluebird bio backed by its founding investors.[1][5] Key leaders like Gianakakos highlighted the unmet need in CVDs, the leading global cause of death, driving the focus on cardiac-specific therapies.[1] Early traction included advancing programs in hypertrophic and dilated cardiomyopathies, with pivotal moments like successful Phase III trials (EXPLORER-HCM and MAVERICK-HCM) and ongoing long-term studies, leading to FDA submission plans.[1][6]
MyoKardia rides the precision medicine trend in biotech, applying genetic subtyping from oncology successes to cardiology, where CVDs cause more deaths than any other disease globally.[1] Timing was ideal post-2012, as targeted therapies gained traction, enabling MyoKardia to pioneer cardiac-specific drugs amid market forces like aging populations and rising heart failure burdens.[1][4] Its influence shaped the ecosystem through Bristol Myers Squibb's acquisition, expanding access to HCM treatments and fostering collaboration in heart failure research, education, and advocacy.[4]
Post-acquisition integration with Bristol Myers Squibb positions MyoKardia's assets like mavacamten for global scaling, with long-term studies and pipeline expansions (e.g., MYK-581 in preclinical) driving sustained impact in cardiomyopathies.[1][4][6] Trends like AI-enhanced patient subtyping and myosin-targeted therapies will shape its legacy, evolving influence toward broader CVD reversal and reduced heart failure burdens. This precision pioneer transforms cardiac care, fulfilling its founding mission to save lives from the world's top killer.[1]
MyoKardia has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Venture Round in August 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2014 | $10.0M Venture Round | Third Rock Ventures |
